Patents Assigned to Entera Bio Ltd.
-
Publication number: 20220151919Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: Entera Bio Ltd.Inventors: Miriam KIDRON, Ehud ARBIT
-
Patent number: 11246827Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: GrantFiled: August 21, 2019Date of Patent: February 15, 2022Assignee: Entera Bio Ltd.Inventors: Miriam Kidron, Ehud Arbit
-
Publication number: 20200138913Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: ApplicationFiled: December 23, 2019Publication date: May 7, 2020Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Patent number: 10583177Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: GrantFiled: February 9, 2016Date of Patent: March 10, 2020Assignee: Entera Bio Ltd.Inventors: Gregory Burshtein, Ariel Rothner, Phillip M. Schwartz, Hillel Galitzer
-
Publication number: 20190380953Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: August 21, 2019Publication date: December 19, 2019Applicant: Entera Bio Ltd.Inventors: Miriam KIDRON, Ehud ARBIT
-
Patent number: 10420721Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: GrantFiled: June 6, 2018Date of Patent: September 24, 2019Assignee: Entera Bio Ltd.Inventors: Miriam Kidron, Ehud Arbit
-
Publication number: 20190209657Abstract: Pharmaceutical compositions comprising a therapeutically active agent and an absorption enhancer such as NAC, NAD, 5-CNAC, 4-MOAC, 4-CNAB or a salt thereof, for use in the treatment of a condition treatable by said therapeutically active agent, are provided. The compositions are for concomitant oral administration of two or more of the unit dosage form, which form together a therapeutically effective amount of the therapeutically active agent and an effective amount of the absorption enhancer. Multi-dose compositions comprising the two or more of the unit dosage form are also provided.Type: ApplicationFiled: August 17, 2017Publication date: July 11, 2019Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180280292Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: June 6, 2018Publication date: October 4, 2018Applicant: Entera Bio Ltd.Inventors: Miriam KIDRON, Ehud ARBIT
-
Patent number: 10010503Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: GrantFiled: November 10, 2015Date of Patent: July 3, 2018Assignee: Entera Bio Ltd.Inventors: Miriam Kidron, Ehud Arbit
-
Publication number: 20180036234Abstract: A pharmaceutical composition for use in the treatment of a medical condition associated with a bone fracture and/or a bone defect is provided herein, wherein the treatment is effected by oral administration of the composition. The composition comprises parathyroid hormone or a fragment thereof, and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate). Further disclosed are uses of the composition in the preparation of a medicament and methods of treating a bone fracture and/or bone defect utilizing the composition.Type: ApplicationFiled: February 9, 2016Publication date: February 8, 2018Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Phillip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20180021272Abstract: A pharmaceutical composition for oral administration is disclosed herein, comprising a therapeutically active agent, SNAC and at least one antacid compound. Further disclosed herein is a pharmaceutical composition unit dosage form for oral administration of a therapeutically active agent is provided herein, the unit dosage form comprising: a core comprising the therapeutically active agent and SNAC (sodium 8-N-(2-hydroxybenzoyl)aminocaprylate); and an external layer comprising at least one protective agent selected from the group consisting of an antacid compound and a protease inhibitor. Methods and uses utilizing the aforementioned pharmaceutical compositions, as well as methods and uses utilizing co-administration, by oral administration, of at least one antacid composition, and a composition comprising the therapeutically active agent and SNAC, are further disclosed herein, for use in treating a condition treatable by oral administration of the therapeutically active agent.Type: ApplicationFiled: February 9, 2016Publication date: January 25, 2018Applicant: Entera Bio Ltd.Inventors: Gregory BURSHTEIN, Ariel ROTHNER, Philip M. SCHWARTZ, Hillel GALITZER
-
Publication number: 20160058699Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: November 10, 2015Publication date: March 3, 2016Applicant: ENTERA BIO LTD.Inventors: Miriam KIDRON, Ehud ARBIT
-
Patent number: 9186412Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: GrantFiled: August 11, 2009Date of Patent: November 17, 2015Assignee: Entera Bio Ltd.Inventors: Miriam Kidron, Ehud Arbit